PAS
NAGE

Point72 Asia (Singapore)’s Niagen Bioscience NAGE Stock Holding History

Point72 Asia (Singapore)’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-352
Closed -$5.07K – 1296
2025
Q2 		$5.07K Buy
+352
New +$3.48K ﹤0.01% 813
2024
Q2 		– Sell
-60,691
Closed -$211K – 1576
2024
Q1 		$211K Buy
+60,691
New +$112K 0.05% 412

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asia (Singapore)'s NAGE Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Niagen Bioscience (NAGE) in Q3 2025, closing a stake of 352 shares — an estimated $5.07K sold.

Point72 Asia (Singapore) first reported a position in NAGE in Q1 2024 and held it in 2 quarters. The position peaked at $211K in Q1 2024. 162 funds tracked by Wall St. Rank hold NAGE as of Q3 2025.

  • Point72 Asia (Singapore) reported no remaining Niagen Bioscience position as of Q3 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 352 Niagen Bioscience shares in Q3 2025, an estimated $5.07K.
  • Point72 Asia (Singapore) first reported a position in Niagen Bioscience in Q1 2024 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Niagen Bioscience position peaked at $211K in Q1 2024.
  • 162 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.